These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 26052378)

  • 1. Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis.
    Polimeni L; Del Ben M; Baratta F; Perri L; Albanese F; Pastori D; Violi F; Angelico F
    World J Hepatol; 2015 Jun; 7(10):1325-36. PubMed ID: 26052378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern approach to the clinical management of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Loffredo L; Angelico F
    World J Gastroenterol; 2014 Jul; 20(26):8341-50. PubMed ID: 25024593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease.
    Sharma N; Chakole S; Wandile B
    Cureus; 2023 Oct; 15(10):e46946. PubMed ID: 38021670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future therapeutic strategies in NAFLD.
    Mark N; de Alwis W; Day CP
    Curr Pharm Des; 2010 Jun; 16(17):1958-62. PubMed ID: 20370671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease and dyslipidemia: An update.
    Katsiki N; Mikhailidis DP; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.
    Del Ben M; Polimeni L; Baratta F; Pastori D; Angelico F
    Br J Clin Pharmacol; 2017 Jan; 83(1):88-95. PubMed ID: 26852185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnosis and treatment of non-alcoholic fatty liver disease.
    Altinbas A; Sowa JP; Hasenberg T; Canbay A
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of non-alcoholic fatty liver disease.
    Sugimoto K; Takei Y
    Hepatol Res; 2011 Oct; 41(10):911-20. PubMed ID: 21951869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Natural Course of Non-Alcoholic Fatty Liver Disease.
    Calzadilla Bertot L; Adams LA
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA; Loomba R
    J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease: pathogenesis and models.
    Zhong H; Dong J; Zhu L; Mao J; Dong J; Zhao Y; Zou Y; Guo M; Ding G
    Am J Transl Res; 2024; 16(2):387-399. PubMed ID: 38463579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.